COVID-19 Resources and Services from WCG:
COVID-19 Webinar Series
Watch the WCG COVID-19 Webinar Series On-Demand
Join thousands of your peers in watching WCG’s webinar series, where clinical trial and public health experts provide the insights on COVID-19 and discuss the biggest questions and topics you submit.
COVID-19 Clinical Trial Tracker
Monitor the progress of clinical trials for COVID-19 treatments and vaccines, leveraging data from the WCG Knowledge Base™.
COVID-19 Trial Insights from the WCG Knowledge Base™
About WCG Trial Insights
The WCG Trial Insights series brings you weekly insights on trial activity throughout the COVID-19 crisis, based on the extensive services we provide to life science clients and supported by our proprietary and powerful WCG Knowledge Base™.
WCG COVID-19 Advisory Services
Need help interpreting critical data to navigate the impact of COVID-19 on trials and sites? We leverage insights and benchmark data from the WCG Knowledge Base to guide best practices for trial performance during this unprecedented time.
Insights from June 11, 2021
Recent Insights from WCG
The map below displays WCG locations. The same locations are listed below the map.
Watch Recent COVID-19 Webinars
Recent news on COVID-19 and clinical trials
News provided by WCG FDAnews and WCG CenterWatch
New Emails Suggest Former FDA Commissioner Hahn Intentionally Made False Claim About Convalescent Plasma
Did former FDA Commissioner Stephen Hahn cave to political pressure from the Trump Administration in authorizing hydroxychloroquine and convalescent plasma as treatments for COVID-19 even though there was scant evidence of their efficacy?
Pfizer Says Its COVID-19 Vaccine Is 100 Percent Effective in Kids 12-15
The two-dose Pfizer-BioNTech COVID-19 vaccine regimen was 100 percent effective in preventing disease in children aged 12-15 years, the companies reported.
CDC Expert Panel Endorses Pfizer, Moderna Boosters for All Adults
Within hours of the FDA authorizing booster doses of the Pfizer and Moderna COVID-19 vaccines for all adults, a Centers for Disease Control and Prevention (CDC) expert panel unanimously supported the decision.
Pfizer Inks $5.29 Billion Pact With U.S. to Supply COVID-19 Antiviral
The U.S. government will pay Pfizer $5.29 billion for 10 million treatment courses of its experimental COVID-19 antiviral, Paxlovid (PF-07321332; ritonavir), to be delivered later this year and into 2022.
AstraZeneca’s Dual-Antibody Injection Cuts Risk of COVID-19 Infection
AstraZeneca’s one-time dual-antibody injection cut the risk of symptomatic COVID-19 by up to 83 percent and the risk of severe disease by 88 percent in two studies of high-risk patients.
Roche Ends Partnership With Atea to Develop COVID-19 Antiviral
Roche paid Atea $350 million upfront to co-develop the antiviral last year, but the companies have since lagged behind other drugmakers.
U.S. to Buy More Doses of COVID-19 Antibody Drug From GSK, Vir
The companies said they will supply an unspecified number of doses by mid-December and that the government has an option to purchase additional doses through March 2022.
Pfizer Applies for EUA for Its Oral COVID-19 Treatment, Inks Deal With Medicines Patent Pool
Pfizer has filed its application with the FDA for Emergency Use Authorization (EUA) of its investigational oral antiviral candidate, Paxlovid, for the treatment of mild-to-moderate COVID-19 in patients at increased risk of hospitalization or death.
Moderna Defends Against Myocarditis Fears in Conference Call
Faced with defending its COVID-19 vaccine in the face of troubling side effects, Moderna held a conference call late last week to discuss the risk of heart inflammation in young people.
EU Adds Rare Spinal Condition to J&J COVID-19 Side Effects
The European Medicines Agency (EMA) has recommended including transverse myelitis, a rare form of spinal inflammation, to the list of Johnson & Johnson (J&J) COVID-19 vaccine side effects.
EMA Endorses COVID-19 Antibody Therapies From Regeneron-Roche, Celltrion
The European Medicines Agency (EMA) has given the thumbs up to two COVID-19 antibody therapies from Regeneron-Roche and Celltrion Healthcare, paving the way for imminent approval by the European Commission.
Moderna and NIH Dig in Over COVID-19 Vaccine Patent Dispute
Moderna and the National Institutes of Health (NIH) are in a patent dispute over the company’s messenger RNA (mRNA)-based COVID-19 vaccine developed with the aid of government scientists.
Expert insights on clinical trials and COVID-19
As we navigate COVID-19 together, our clinical trial experts are engaged to address the biggest questions. To submit a topic or question, use the form at the bottom of the page.
Submit a COVID-19 question or topic to be considered in future webinars
Please note: protocol-specific questions for studies under the oversight of a WCG IRB should be submitted through your IRB contact person, not through this form.
Disclaimer: All information available on this site is intended for your general knowledge and is not for the purpose of providing regulatory advice, medical advice, or a substitute for institutional review board review. You should not use this information to determine compliance with any applicable laws or regulations governing institutional review boards and human subjects research.